Literature DB >> 11403934

High specificity of human orexin receptors for orexins over neuropeptide Y and other neuropeptides.

T Holmqvist1, K E Akerman, J P Kukkonen.   

Abstract

Orexin- and neuropeptide Y-ergic systems show physiological interaction in the regulation of appetite. In this study we investigate the postulated effect of neuropeptide Y (NPY) and other peptides directly on orexin OX1 and OX2 receptors. None of the tested peptides (NPY-variants, secretin, alpha-melanocortin, pancreatic polypeptide or pituitary adenylyl cyclase-activating peptide-38) induced any Ca2+ elevation at the concentrations up to 300 nM (human NPY, secretin and alpha-melanocortin up to 1 microM). Orexin-A- and -B-mediated Ca2+ elevations were completely unaffected by the peptides. In binding assays, human NPY, secretin and alpha-melanocortin at 1 microM did not induce any displacement of 0.1 nM [125I]orexin-A. Thus, in contrast to the previously reported result on orexin-A binding, our results demonstrate that NPY does not directly interact with orexin receptor in intact cellular settings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403934     DOI: 10.1016/s0304-3940(01)01839-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

Review 1.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

2.  Tumor necrosis factor-alpha regulates the Hypocretin system via mRNA degradation and ubiquitination.

Authors:  Shuqin Zhan; Guo-Qiang Cai; Anni Zheng; Yuping Wang; Jianping Jia; Haotian Fang; Youfeng Yang; Meng Hu; Qiang Ding
Journal:  Biochim Biophys Acta       Date:  2010-11-18

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 4.  Orexin: pathways to obesity resistance?

Authors:  Tammy A Butterick; Charles J Billington; Catherine M Kotz; Joshua P Nixon
Journal:  Rev Endocr Metab Disord       Date:  2013-12       Impact factor: 6.514

5.  Orexin receptors in GtoPdb v.2021.3.

Authors:  Paul Coleman; Luis de Lecea; Anthony Gotter; Jim Hagan; Daniel Hoyer; Thomas Kilduff; Jyrki P Kukkonen; Rod Porter; John Renger; Jerome M Siegel; Gregor Sutcliffe; Neil Upton; Christopher J Winrow
Journal:  IUPHAR BPS Guide Pharm CITE       Date:  2021-09-02

6.  Expression of orexin A and its receptor 1 in the human prostate.

Authors:  Salvatore Valiante; Giovanna Liguori; Simona Tafuri; Roberto Campese; Roberto Monaco; Salvatore Paino; Vincenza Laforgia; Norma Staiano; Alfredo Vittoria
Journal:  J Anat       Date:  2013-02-21       Impact factor: 2.610

7.  Orexin A decreases lipid peroxidation and apoptosis in a novel hypothalamic cell model.

Authors:  Tammy A Butterick; Joshua P Nixon; Charles J Billington; Catherine M Kotz
Journal:  Neurosci Lett       Date:  2012-07-11       Impact factor: 3.046

8.  Origin of secretin receptor precedes the advent of tetrapoda: evidence on the separated origins of secretin and orexin.

Authors:  Janice K V Tam; Kwan-Wa Lau; Leo T O Lee; Jessica Y S Chu; Kwong-Man Ng; Alain Fournier; Hubert Vaudry; Billy K C Chow
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

9.  Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis.

Authors:  A Nuñez; M L Rodrigo-Angulo; I De Andrés; M Garzón
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Hypocretin (orexin) regulates glutamate input to fast-spiking interneurons in layer V of the Fr2 region of the murine prefrontal cortex.

Authors:  Patrizia Aracri; Daniele Banfi; Maria Enrica Pasini; Alida Amadeo; Andrea Becchetti
Journal:  Cereb Cortex       Date:  2013-12-01       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.